Severe deficiency of the fatty acid amide hydrolase (FAAH) activity segregates with the Huntington's disease mutation in peripheral lymphocytes

Neurobiology of Disease

Volumn 27, Issue 1, 2007, Pages 108-116

  Battista, Natalia ^a,b   Bari, Monica ^b,c   Tarditi, Alessia ^d   Mariotti, Caterina ^e   Bachoud Lévi, Anne Catherine ^f   Zuccato, Chiara ^d   Finazzi Agrò, Alessandro ^c   Genitrini, Silvia ^e   Peschanski, Marc ^g   Di Donato, Stefano ^e   Cattaneo, Elena ^d   Maccarrone, Mauro ^a,b  

^a UNIVERSITY OF TERAMO   (Italy)

^b IRCCS FONDAZIONE SANTA LUCIA   (Italy)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e DEPARTMENT OF NEUROSURGERY   (Italy)

^f INSERM   (France)

^g I Stem   (France)

Author keywords

Endocannabinoid; Enzyme inhibition; FAAH; Huntington's disease; Lymphocyte

Indexed keywords

ENDOCANNABINOID; FATTY ACID AMIDASE;

ADULT; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME DEGRADATION; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; HUNTINGTON CHOREA; MAJOR CLINICAL STUDY; MALE; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADULT; AMIDOHYDROLASES; BIOLOGICAL MARKERS; BIOLOGICAL TRANSPORT; BRAIN; FEMALE; HUMANS; HUNTINGTON DISEASE; LYMPHOCYTES; MALE; MIDDLE AGED; RECEPTORS, CANNABINOID; TRPV CATION CHANNELS;

EID: 34250361495     PISSN: 09699961     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nbd.2007.04.012     Document Type: Article

References (26)

1. Borovecki F., Lovrecic L., Zhou J., Jeong H., Then F., Rosas H.D., M. Hersch S., Hogarth P., Bouzanou B., Jensen R.V., and Krainc D. Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11023-11028
2. Bracey M.H., Hanson M.A., Masuda K.R., Stevens R.C., and Cravatt B.F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298 (2002) 1793-1796
3. Cattaneo E., Zuccato C., and Tartari M. Normal huntigtin function: an alternative approach to Huntington disease. Nat. Rev., Neurosci. 6 (2005) 919-930
4. Centonze D., Rossi S., Prosperetti C., Tscherter A., Bernardi G., Maccarrone M., and Calabresi P. Abnormal sensitivity to cannabinoid receptor stimulation might contribute to altered GABA transmission in the striatum of R6/2 Huntington's disease mice. Biol. Psychiatry 57 (2005) 1583-1589
5. Fernandez-Ruiz J., Gonzalez S., Romero J., and Ramos J.A. Cannabinoids in neurodegeneration and neuroprotection. In: Mechoulam R. (Ed). Cannabinoids as Therapeutics (2005), Birkhauser Verlag, Berlin 79-109
6. Fezza F., Gasperi V., Mazzei C., and Maccarrone M. Radiochromatographic assay of N-acyl-phosphatidylethanolamine-specific phospholipase D (NAPE-PLD) activity. Anal. Biochem. 339 (2005) 113-120
7. Grigorenko E., Kittler J., Clayton C., Wallace D., Zhuang S., Bridges D., Bundey S., Boon A., Pagget C., Hayashizaki S., Lowe G., Hampson R., and Deadwyler S. Assessment of cannabinoid induced gene changes: tolerance and neuroprotection. Chem. Phys. Lipids 121 (2002) 257-266
8. Heiser V., Engemann S., Brocker W., Dunkel I., Boeddrich A., Waelter S., Nordhoff E., Lurz R., Schugardt N., Rautenberg S., Herhaus C., Barnickel G., Bottcher H., Lehrach H., and Wanker E. Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16400-16406
9. Huntington Study Group. The Unified Huntington's Disease Rating Scale: reliability and consistency. Mov. Dis. 11 (1996) 136-142
10. Ide K., Nukina N., Masuda N., Goto J., and Kanazawa I. Abnormal gene product identified in Huntington's disease lymphocytes and brain. Biochem. Biophys. Res. Commun. 209 (1995) 1119-1125
11. Klein T.W., Newton C., Larsen K., Lu L., Perkins I., Nong L., and Friedman H. The cannabinoid system and immune modulation. J. Leukoc. Biol. 74 (2003) 486-496
12. Lastres-Becker I., De Miguel R., and Fernandez-Ruiz J.J. The endocannabinoid system and Huntington's disease. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 335-347
13. 2 receptors and metabolic stability. J. Med. Chem. 41 (1998) 5353-5361
14. Maccarrone M., Valensise H., Bari M., Lazzarin N., Romanini C., and Finazzi-Agrò A. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet 355 (2000) 1326-1329
15. Maccarrone M., Valensise H., Bari M., Lazzarin N., Romanini C., and Finazzi-Agrò A. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J. Immunol. 166 (2001) 7183-7189
16. Maccarrone M., Barboni B., Paradisi A., Bernabò N., Gasperi V., Pistilli M.G., Fezza F., Lucidi P., and Mattioli M. Characterization of the endocannabinoid system in boar spermatozoa and implications for sperm capacitation and acrosome reaction. J. Cell Sci. 118 (2005) 4393-4404
17. Marder K., Zhao H., Myers R.H., Cudkowicz M., Kayson E., Kieburtz K., Orme C., Paulsen J., Penney Jr. J.B., Siemers E., and Shoulson I. Rate of functional decline in Huntington's disease. Huntington Study Group. Neurology 54 (2000) 452-458
18. McKinney M.K., and Cravatt B.F. Structure and function of fatty acid amide hydrolase. Annu. Rev. Biochem. 74 (2005) 411-432
19. Oddi S., Bari M., Battista N., Barsacchi D., Cozzani I., and Maccarrone M. Confocal microscopy and biochemical analysis reveal spatial and functional separation between anandamide uptake and hydrolysis in human keratinocytes. Cell. Mol. Life Sci. 62 (2005) 386-395
20. Pertwee R.G., and Ross R.A. Cannabinoid receptors and their ligands. Prostaglandins Leukot. Essent. Fat. Acids 66 (2002) 101-121
21. Rocío S., de la Vega L., Macho A., Appendino G., Di Marzo V., and Muñoz E. Mechanisms of HIV-1 inhibition by the lipid mediator N-arachidonoyldopamine. J. Immunol. 175 (2005) 3990-3999
22. Ross R.A., Gibson T.M., Brockie H.C., Lesile M., Pashmi G., Craib S.J., Di Marzo V., and Pertwee R.G. Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol. 132 (2001) 631-640
23. Sipione S., and Cattaneo E. Modeling Huntington's disease in cells, flies, and mice. Mol. Neurobiol. 23 (2001) 21-51
24. Trouillas P., Takayanagi T., Hallett M., Currier R.D., Subramony S.H., Wessel K., Bryer A., Diener H.C., Massaquoi S., Gomez C.M., Coutinho P., Ben Hamida M., Campanella G., Filla A., Schut L., Timann D., Honnorat J., Nighoghossian N., and Manyam B. International Cooperative Ataxia Rating Scale for pharmacological assessment of the cerebellar syndrome. The Ataxia Neuropharmacology Committee of the World Federation of Neurology. J. Neurol. Sci. 145 (1997) 205-211
25. 2A receptor function in peripheral blood cells in Huntington's disease. FASEB J. 17 (2003) 2148-2150
26. Zuccato C., Liber D., Ramos C., Tarditi A., Rigamonti D., Tartari M., Valenza M., and Cattaneo E. Progressive loss of BDNF in a mouse model of Huntington's disease and rescue by BDNF delivery. Pharmacol. Res. 52 (2005) 133-139